scholarly journals Efficacy of Two Commercial Ready-To-Use PCV2 and Mycoplasma hyopneumoniae Vaccines under Field Conditions

Animals ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 1553
Author(s):  
Gonzalo López-Lorenzo ◽  
Alberto Prieto ◽  
Cynthia López-Novo ◽  
Pablo Díaz ◽  
Ceferino Manuel López ◽  
...  
Keyword(s):  
Preventive Measure ◽  
Mycoplasma Hyopneumoniae ◽  
Porcine Circovirus Type ◽  
Daily Weight Gain ◽  
Porcine Circovirus ◽  
Lung Lesions ◽  
Unvaccinated Control ◽  
Parity Number ◽  
Group A ◽  
Group B

Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae are economically important pathogens in swine farms. Vaccination is the main preventive measure for both infections. In order to test two ready-to-use bivalent vaccines, 646 piglets from a herd actively infected with both pathogens were stratified according to the sow parity number and randomly assigned to three groups: A and B were vaccinated with two different vaccines, respectively, while C remained as the unvaccinated control. Vaccine efficacy was assessed based on the weight, average daily weight gain (ADWG), degree of lung lesions, presence of PCV2 viremia by qPCR and presence of PCV2 and M. hyopneumoniae antibody levels by ELISA. Our data revealed that the sow parity did not influence the vaccine outcomes. Good results for most of the analyzed parameters were observed in both vaccinated groups. ADGW and final weight were higher and lung lesions were less evident in both vaccinated groups than in the control one, but only Group A showed a significant improvement. PCV2 viremia was not detected in Group A, but it did appear in Group B coinciding with its peak in Group C. Finally, both the PCV2 and M. hyopneumoniae serological patterns differed depending on the employed vaccine.

scholarly journals Effectiveness of two intramuscular combined vaccines for the control of Mycoplasma hyopneumoniae and porcine circovirus type 2 in growing pigs: a randomized field trial

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Gwenaël Boulbria ◽  
Sophie Brilland ◽  
Charlotte Teixeira-Costa ◽  
Mathieu Brissonnier ◽  
Mathieu Charles ◽  
...  
Keyword(s):  
Field Trial ◽  
Mycoplasma Hyopneumoniae ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Growing Pigs ◽  
Porcine Circovirus ◽  
Lung Lesions ◽  
Growth Performances ◽  
Group A

Abstract Background Mycoplasma hyopneumoniae and Porcine circovirus type 2 are two economically important pathogens affecting growing pigs. Control and prevention of both diseases can be accomplished by vaccination, together with biosecurity and good management practices. Many commercial vaccines are available. The aim of this study was to assess the efficacy of Hyogen® and Circovac® administered mixed at weaning and to compare this protocol with a competitor ready-to-use (RTU) vaccine. Case presentation A randomised field trial was designed in a commercial farrow-to-finish farm located in France. A total of 641 pigs born from 54 different sows were included in this study. Piglets at weaning were allocated into three groups: the first one vaccinated with Hyogen® and Circovac® combined (group A), the second one vaccinated with a competitor RTU vaccine (group B) and the last one unvaccinated. Only minor local reactions for both vaccination groups could be observed which revealed a good safety of both protocols. Both vaccination schemes in this trial didn’t improve wean-to-slaughter growth performances but significantly reduced lung lesions, lung fissures and pleurisy at slaughter, produced a seroconversion for both M. hyopneumoniae and PCV-2 and significantly reduced the PCV-2 viral load in blood. When we compared groups A and B, we observed no significant differences in growth performances, mortality, clinical signs, percentages of affected lungs at slaughter, lung fissures and pleurisy, and no difference in pathogens detection. However, two statistical differences were observed between both vaccines: the mean lung lesion score and the percentage of extensive lung lesions were lower in group A. This is consistent with lower M. hyopneumoniae loads in the lower respiratory tract in pigs from group A but this difference was not statistically significant. Conclusions Results reported in this case study must be considered with caution since it was done in only one farm. In this trial, Hyogen® and Circovac® mixed together under field conditions offered a successful protection of growing pigs and significantly decreased the extension of lung lesions during a natural field challenge when compared with a competitor RTU vaccine.

scholarly journals Effects of Porcine Circovirus Type 2 (PCV2) Maternal Antibodies on Experimental Infection of Piglets with PCV2

2005 ◽  
Vol 12 (11) ◽  
pp. 1347-1351 ◽  
Author(s):  
N. E. McKeown ◽  
T. Opriessnig ◽  
P. Thomas ◽  
D. K. Guenette ◽  
F. Elvinger ◽  
...  
Keyword(s):  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Pcv2 Infection ◽  
Maternal Antibodies ◽  
Porcine Circovirus ◽  
Enzyme Linked Immunosorbent Assay ◽  
Group A ◽  
Group B ◽  
Group D

ABSTRACT To determine the effects of porcine circovirus type 2 (PCV2) maternal antibodies on and response to experimental PCV2 infection, 24 piglets were divided into four groups on the basis of the enzyme-linked immunosorbent assay titers of PCV2 maternal antibodies: group A (n = 6; sample/positive [S/P] ratio, <0.2), group B (n = 5; S/P ratio, >0.2 to <0.5), and groups C (n = 8) and D (n = 5) (S/P ratio, >0.5). Piglets in groups A, B, and C were inoculated with PCV2 at day 0 and challenged with PCV2 at day 42. Group D piglets were not exposed to PCV2 at day 0 but were challenged at day 42. Before challenge, seroconversion to PCV2 antibodies occurred in five of six group A piglets, and the antibody level rose above the cutoff level in one of five group B piglets. Viremia was detected in five of six, four of five, and two of eight pigs in groups A, B, and C, respectively. After challenge, PCV2 DNA was detectable from 7 to 21 days postchallenge in the sera from six of six, four of five, three of eight, and five of five pigs in groups A, B, C, and D, respectively. The results indicated that protection against PCV2 infection conferred by maternal antibodies is titer dependent: higher titers are generally protective, but low titers are not.

Replication and transmission of porcine circovirus type 2 in mice

2008 ◽  
Vol 56 (3) ◽  
pp. 421-427 ◽  
Author(s):  
Attila Cságola ◽  
Daniel Cadar ◽  
Tamás Tuboly
Keyword(s):  
Animal Experiments ◽  
Porcine Circovirus Type ◽  
Virus Genome ◽  
Oral Route ◽  
Porcine Circovirus Type 2 ◽  
Porcine Circovirus ◽  
Post Inoculation ◽  
Group A ◽  
Group B

Little information is known about infection, replication and transmission of porcine circovirus type 2 (PCV2) in species other than swine. Two sets of animal experiments were carried out to investigate the susceptibility of mice to PCV2 and to study their possible role in maintaining and transmitting the virus. In the first experiment 14 mice were inoculated with PCV2 by the intraperitoneal route with 5 × 10 2 TCID 50 of the PCV2-ROM strain (Cadar et al., 2007). In a second experiment 24 mice were divided into two groups (A and B); mice in Group A (n = 18) were inoculated orally with 1 × 10 5 TCID 50 PCV2-ROM and mice in Group B (n = 6) were left uninoculated until day 12 post inoculation (p.i.), when they were mixed with Group A. The animals were sacrificed at intervals for postmortem investigation and virus genome detection by polymerase chain reaction (PCR). The PCR results indicated that PCV2 could replicate in mice infected intraperitoneally or by the oral route, and that the virus can be transmitted directly from mouse to mouse.

Immunoenhancement of Recombinant Neisseria meningitides PorB Protein on Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae Genetically Engineered Vaccines

2019 ◽  
Vol 26 (10) ◽  
pp. 776-784
Author(s):  
Rui Yang ◽  
Yu Tao ◽  
Gaojian Li ◽  
Jian Chen ◽  
Jianhong Shu ◽  
...  
Keyword(s):  
Recombinant Protein ◽  
Mycoplasma Hyopneumoniae ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Genetically Engineered ◽  
Porcine Circovirus ◽  
Practical Applications ◽  
Neisseria Meningitides ◽  
Short Period

Background:Porcine circovirus and Mycoplasma hyopneumoniae can cause respiratory diseases in pigs, which cause serious economic loss in the worldwide pig industry. Currently, these infections are mainly prevented and controlled by vaccination. The new vaccines on the market are mainly composed of subunits and inactivated vaccines but usually have lower antigenicity than traditional live vaccines. Thus, there is an increasing need to develop new adjuvants that can cause rapid and long-lasting immunity to enhance the antigenic efficacy for vaccines. Studies have shown that meningococcal porin PorB can act as a ligand to combine with Toll-like receptors to activate the production of immunological projections and act as a vaccine immunological adjuvant.Objective:In this article, we expressed and purified the recombinant PorB protein and verified its immunogenicity against porcine circovirus type 2 and Mycoplasma hyopneumoniae genetically engineered vaccine.Methods:In this article, we used prokaryotic expression to express and purify recombinant PorB protein, four different concentrations of PorB protein, Freund's adjuvant with two genetically engineered vaccines were combined with subcutaneous immunization of mice.Results:Our study shows that the appropriate dose of the recombinant protein PorB can enhance the levels of humoral and cellular responses induced by two genetically engineered vaccines in a short period of time in mice. The PorB adjuvant group may cause statistically higher antibody titers for both genetically engineered vaccines compared to Freund's commercial adjuvant (P<0.001).Conclusion:The recombinant protein PorB may be a good candidate adjuvant for improving the protective effect of vaccines against porcine circovirus type 2 and Mycoplasma hyopneumoniae, and the protein can be used for future practical applications.

scholarly journals A Comparison of Virulence of Three Porcine Circovirus Type 2 (PCV2) Genotypes (a, b, and d) in Pigs Singularly Inoculated with PCV2 and Dually Inoculated with PCV2 and Porcine Reproductive and Respiratory Syndrome Virus

Pathogens ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 891
Author(s):  
Jeongmin Suh ◽  
Taehwan Oh ◽  
Keehwan Park ◽  
Siyeon Yang ◽  
Hyejean Cho ◽  
...  
Keyword(s):  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Daily Weight Gain ◽  
Porcine Circovirus ◽  
Respiratory Syndrome Virus ◽  
Average Daily Weight Gain ◽  
Significant Difference ◽  
Lesion Severity ◽  
Severe Lung

The aim of this study was to compare the virulence of porcine circovirus type 2 (PCV2) genotypes in dually inoculated pigs with both three genotypes (a, b, and d) of PCV2 and porcine reproductive and respiratory syndrome virus-2 (PRRSV-2) versus pigs singularly inoculated with the same three PCV2 genotypes (a, b, and d). Differences in this comparison were found in PCV2 viremia levels, lung and lymphoid lesion severity, and the amount of PCV2 antigen within the lymphoid lesions. Regardless of PCV2 genotypes, pigs that were dually inoculated with PCV2/PRRSV had significantly higher clinical scores, less average daily weight gain, higher levels of PCV2 viremia, and more severe lug and lymphoid lesions compared to pigs singularly inoculated with PCV2. Among the dually infected pig groups, pigs infected with PCV2d/PRRSV-2 had significantly higher levels of PCV2 viremia, more severe lung and lymphoid lesions, and more PCV2-positive cells within lymphoid lesions compared to pigs dually inoculated with PCV2a/PRRSV-2 and PCV2b/PRRSV-2. The results of this study demonstrated significant differences in the virulence among dual inoculation of PCV2a/PRRSV-2, PCV2b/PRRSV-2, and PCV2d/PRRSV-2. A significant difference in the virulence among PCV2a, PCV2b, and PCV2d single-inoculated pig groups was not found with respect to the levels of PCV2 viremia and production of PCV2-associated lymphoid lesions.

scholarly journals Field efficacy study of a novel ready-to-use vaccine against mycoplasma hyopneumoniae and porcine circovirus type 2 in a Greek farm

2015 ◽  
Vol 1 (1) ◽  
Author(s):  
Eleni D. Tzika ◽  
Panagiotis D. Tassis ◽  
Dimitrios Koulialis ◽  
Vassileios G. Papatsiros ◽  
Tom Nell ◽  
...  
Keyword(s):  
Mycoplasma Hyopneumoniae ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Porcine Circovirus ◽  
Efficacy Study ◽  
Field Efficacy

scholarly journals The Efficacy of Ranikhet Disease Vaccines Produced by Livestock Research Institute of Bangladesh

2013 ◽  
Vol 1 (1) ◽  
pp. 9-13 ◽  
Author(s):  
Sreebas Chandra Sarkar ◽  
Sukumar Saha ◽  
Md Mansurul Amin ◽  
Md Golzar Hossain
Keyword(s):  
Field Isolate ◽  
Challenge Infection ◽  
Control Group ◽  
Passive Protection ◽  
Field Virus ◽  
Unvaccinated Control ◽  
Antibody Titers ◽  
Group A ◽  
Group B ◽  
Research Institute

The study was conducted to investigate the efficacy of Baby chick Ranikhet Disease Vaccine (BCRDV) and Ranikhet Disease Vaccine (RDV) produced by the Livestock Research Institute (LRI), Mohakhali, Dhaka. For this experiment, 100 day-old-chick was purchased from Phinex Hatchery Ltd., Gazipur. The chicks (n=100) were divided into two groups. In group A (n=50), vaccination was performed twice with BCRDV at 2 and 21 days of age through intraocular route (i/o) followed by once with RDV at 60-day of age through intramuscular (i/m) route. Group B (n=50) was kept as unvaccinated control. The immunogenicity of the vaccine was evaluated by measuring the serum HI antibody titers at 1-, 20-, 36-, and 76-day of age, while the vaccine efficacy was examined by a challenge infection experiment with a velogenic field isolate of NDV as well as passive protection test. It was observed that the maternal antibody titers of the unvaccinated control group B gradually declined from day 1 to day 76 of age. Conversely, after primary and secondary vaccination with BCRDV, the levels of serum HI titer slightly increased in vaccinated group A compared with those in control group B. Finally administration of RDV resulted in a sharp increase in HI titer, leading to protection from challenge infection with virulent field virus as well as passive protection test. These results clearly demonstrated that a prime-booster immunization with BCRDV and RDV, both produced by LRI, is effective to protect chicken against Newcastle disease (ND).DOI: http://dx.doi.org/10.3329/mh.v1i1.13706 Microbes and Health Vol.1(1) June 2012 pp.9-13

scholarly journals Comparison of porcine circovirus type 2 (PCV2)-associated lesions produced by co-infection between two genotypes of PCV2 and two genotypes of porcine reproductive and respiratory syndrome virus

2014 ◽  
Vol 95 (11) ◽  
pp. 2486-2494 ◽  
Author(s):  
Changhoon Park ◽  
Hwi Won Seo ◽  
Su-Jin Park ◽  
Kiwon Han ◽  
Chanhee Chae
Keyword(s):  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Daily Weight Gain ◽  
Porcine Circovirus ◽  
Respiratory Syndrome Virus ◽  
Associated Lesions ◽  
Significant Difference ◽  
Concurrent Infections

The objective of this study was to compare the virulence and pathogenicity of a combination of concurrent infections of two genotypes of porcine circovirus type 2 (PCV2) and two genotypes of porcine reproductive and respiratory syndrome virus (PRRSV) in terms of PCV2 viraemia, and PCV2-associated lesions and antigens in co-infected pigs. Pigs with PCV2a (or 2b)/type 1 (or type 2) PRRSV had significantly (P<0.05) higher mean clinical respiratory scores and lower average daily weight gain compared with pigs with PCV2a (or 2b). Co-infection induced significantly lower levels of anti-PCV2 and anti-PRRSV IgG antibodies than infection with one genotype alone, regardless of the genotype of the two viruses. Pigs with PCV2a (or 2b)/type 2 PRRSV had significantly (P<0.05) higher levels of PCV2 viraemia, more severe PCV2-associated lesions, and more PCV2 DNA within the lesions compared with pigs with PCV2a (or 2b)/type 1 PRRSV. However, there was no significant difference in these parameters in pigs with PCV2a/type 2 PRRSV or PCV2b/type 2 PRRSV. The results of this study demonstrate significant differences in the virulence and pathogenicity of type 1 and type 2 PRRSV but no significant differences in the virulence and pathogenicity of PCV2a and PCV2b with respect to the production of PCV2-associated lesions.

Sign in / Sign up

Export Citation Format

Share Document